Zobrazeno 1 - 10
of 404
pro vyhledávání: '"rotarix™"'
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 584-596 (2024)
Introduction Rotavirus is a leading cause of severe diarrheal disease and death in children under five years of age worldwide. Vaccination is one of the most important public health interventions to reduce this significant burden.Areas covered This l
Externí odkaz:
https://doaj.org/article/4ef3cbb2f8124cd89202124fdd3c093c
Autor:
Saori Fukuda, Masanori Kugita, Kanako Kumamoto, Yuki Akari, Yuki Higashimoto, Shizuko Nagao, Takayuki Murata, Tetsushi Yoshikawa, Koki Taniguchi, Satoshi Komoto
Publikováno v:
Viruses, Vol 16, Iss 8, p 1198 (2024)
The live attenuated human rotavirus vaccine strain RIX4414 (Rotarix®) is used worldwide to prevent severe rotavirus-induced diarrhea in infants. This strain was attenuated through the cell culture passaging of its predecessor, human strain 89-12, wh
Externí odkaz:
https://doaj.org/article/3a7422a463114020bd489b9a564a38c9
Autor:
Catherine Cohet, Brigitte Cheuvart, Leentje Moerman, Dan Bi, Adrian Caplanusi, Mallesh Kariyappa, Sanjay Lalwani, Monjori Mitra, Amita Sapru, Shruti Saha, P.V. Varughese, Rajeev Zachariah Kompithra, Sanjay Gandhi
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4646-4653 (2021)
The human rotavirus vaccine (HRV; Rotarix, GSK) is available as liquid (Liq) and lyophilized (Lyo) formulations, but only Lyo HRV is licensed in India. In this phase III, randomized, open-label trial (NCT02141204), healthy Indian infants aged 6–10
Externí odkaz:
https://doaj.org/article/5d35f76d2617450b9901c97811e1abfb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rahinatou N. Ghapoutsa, Maurice Boda, Rashi Gautam, Valantine Ngum Ndze, Akongnwi E. Mugyia, Francois-Xavier Etoa, Michael D. Bowen, Mathew D. Esona
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Despite the global roll-out of rotavirus vaccines (RotaTeq/Rotarix / ROTAVAC/Rotasiil), mortality and morbidity due to group A rotavirus (RVA) remains high in sub-Saharan Africa, causing 104,000 deaths and 600,000 hospitalizations
Externí odkaz:
https://doaj.org/article/7e6043e079c84fcfbbb410c1e668b40b
Autor:
Dung Thi Thuy Truong, Ji-Man Kang, Ngoc Thi Hong Tran, Lan Trong Phan, Hung Thanh Nguyen, Thang Vinh Ho, Thao Thi Thanh Nguyen, Phuc Le Hoang, Trang Mai Thuy Pham, Thuy Dieu Nguyen, Thang Anh Hoang, Quang Chan Luong, Quang Duy Pham, Jong Gyun Ahn, Sangchul Yoon, Thuong Vu Nguyen, Joon-Sup Yeom
Publikováno v:
International Journal of Infectious Diseases, Vol 105, Iss , Pp 277-285 (2021)
Objectives: Rotavirus (RV) genotypes vary geographically, and this can affect vaccine effectiveness (VE). This study investigated the genotype distribution of RV and explored VE before introducing the RV vaccine to the national immunization programme
Externí odkaz:
https://doaj.org/article/8acfa085e759468aa20932e714abc269
Autor:
Joshua Ndung’u Gikonyo, Betty Mbatia, Patrick W. Okanya, George F.O. Obiero, Carlene Sang, Duncan Steele, James Nyangao
Publikováno v:
International Journal of Infectious Diseases, Vol 100, Iss , Pp 434-440 (2020)
Background: Rotaviruses are primary etiological agents of gastroenteritis in young children. In Kenya, G1P8 monovalent vaccine (Rotarix) was introduced in July 2014 for mandatory vaccination of all newborns at 6 and 10 weeks of age. Since then, no st
Externí odkaz:
https://doaj.org/article/53264c50f5c140db83ad411d86569733
Autor:
Natasha Makabilo Laban, Samuel Bosomprah, Michelo Simuyandi, Mwelwa Chibuye, Adriace Chauwa, Masuzyo Chirwa-Chobe, Nsofwa Sukwa, Chikumbutso Chipeta, Rachel Velu, Katanekwa Njekwa, Cynthia Mubanga, Innocent Mwape, Martin Rhys Goodier, Roma Chilengi
Publikováno v:
Vaccines, Vol 11, Iss 2, p 346 (2023)
Oral rotavirus vaccines show diminished immunogenicity in low-resource settings where rotavirus burden is highest. This study assessed the safety and immune boosting effect of a third dose of oral ROTARIX® (GlaxoSmithKline) vaccine administered at 9
Externí odkaz:
https://doaj.org/article/213c2e9883764f5c90ad94789823ed1b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.